Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo, Bayer Vital Collaborate To Look for Cancer Treatment Biomarkers

NEW YORK (GenomeWeb News) – The German biotech company Kinaxo Biotechnologies, a spinout of the Max Planck Institute, and Bayer Vital announced today that they have formed a collaboration to identify novel phosphoproteomics biomarkers for predicting cancer treatment outcomes.

The researchers plan to use Kinaxo's quantitative phosphoproteomics technology, PhosphoScout, to find and quantify phosphorylation sites as part of a clinical trial conducted by Bayer Vital on the use of oral anti-cancer drug sorafenib (Nexavar) in acute myeloid leukemia.

The drug, which has already been approved for treating hepatocellular carcinoma and renal cell carcinoma, is known to inhibit several kinases involved in pathways governing cellular growth and blood vessel formation.

For the current study, the team plans to use phosphoproteomics approaches to look at how cellular phosphorylation patterns change in response to drug treatment and to try to find biomarkers for predicting treatment outcomes.

"Both partners aim at investigating innovative technologies (such as phosphoproteomics) and targeted therapies (such as kinase inhibitors) which — in conjunction — should allow more effective cancer treatments and, thus, provide more hope to cancer patients," Erich Enghofer, head of Bayer Healthcare's oncology business unit, said in a statement.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.